

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Haruo SUGIYAMA

SERIAL NO: 10/594,507

GAU:

FILED: September 28, 2006

EXAMINER:

FOR: CANCER ANTIGEN PEPTIDES DERIVED FROM WT1

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- ☐ Online credit card payment is being made in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- ☐ Online credit card payment is being made in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

| | | | | | | | |
|--|----|--|----------|---|-----------------------|--------------------------|--|
| Form PTO 1449 (Modified) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY DOCKET NO. 296846US0PCT | | SERIAL NO. 10/594,507 | |
| LIST OF REFERENCES CITED BY APPLICANT | | | | APPLICANT Haruo SUGIYAMA | | | |
| | | | | FILING DATE September 28, 2006 | | GROUP | |
| | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE |
| | AA | 7 030 212 | 04-18-06 | SUGIYAMA, et al. | | | |
| | AB | | | | | | |
| | AC | | | | | | |
| | AD | | | | | | |
| | AE | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES NO | | |
| | AF | 2002 525099 | 08-13-02 | JP (equivalent of US 2003 0039635 and WO 00 18795) | | | NO |
| | AG | 00 26249 | 05-11-00 | WO | | | NO |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |
| | AM | | | | | | |
| | AN | | | | | | |
| | AO | | | | | | |
| OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) | | | | | | | |
| | AP | ZINSZNER, H. et al., "Nucleotide Sequence of the HLA_A26 Class I Gene: Identification of Specific Residues and Molecular Mapping of Public HLA Class I Epitopes" Human Immunology, Vol. 27, pgs. 155-166, 1990. | | | | | |
| | AQ | BELLANTUONO, I. et al., "Two Distinct HLA-A0201-Presented Epitopes of the Wilms Tumor Antigen 1 Can Function as Targets for Leukemia-Reactive CTL" Blood, Vol. 100, No. 10, pgs. 3835-3837, 2002. | | | | | |
| | AR | LIQUAN, G. et al., "Selective Elimination of Leukemic CD34 ⁺ Progenitor Cells by Cytotoxic T Lymphocytes Specific for WT1", Blood, Vol. 95, No. 7, pgs. 2198-2203, 2000. | | | | | |
| | AS | "Funakoshi News", Frontiers in Life Science, No. 2004 Nen 3 Gatsu 1 Nichi, pgs. 1-13, 2004. (With English Translation) | | | | | |
| | AT | DAL PORTO, J. et al., "A Soluble Divalent Class I Major Histocompatibility Complex Molecule Inhibits Alloreactive T Cells at Nanomolar Concentrations", Proc. Natl. Acad. Sci. USA, Vol. 90, pgs. 6671-6675, 1993. | | | | | |
| | AU | CALL, K.M. et al., "Isolation and Characterization of a Zinc Finger Polypeptide Gene at the Human Chromosome 11 Wilms' Tumor Locus", Cell Press, Vol. 60, pgs. 509-520, 1990. | | | | | |
| | AV | GESSLER, M. et al., "Homozygous Deletion in Wilms Tumours of a Zinc-Finger Gene Identified by Chromosome Jumping", Letters to Nature, Vol. 343, pgs. 774-778, 1990. | | | | | |
| | AW | MENKE, A. L. et al., "The Wilms' Tumor 1 Gene: Oncogene or Tumor Suppressor Gene?" International Review of Cytology, Vol. 181, pgs. 151-212, 1998. | | | | | |
| | AX | SUGIYAMA, H., "Cancer Immunotherapy Targeting WT1 Protein", International Journal of Hematology, Vol. 76, pgs. 127-132, 2002. | | | | | |
| | AY | | | | | | |
| | AZ | | | | | | <input type="checkbox"/> Additional References sheet(s) attached |
| Examiner | | | | | Date Considered | | |
| *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

U.S. PCT Application Serial No: 10/594,507

Filed: September 28, 2006

Haruo SUGIYAMA

Docket No. 296846US0PCT

STATEMENT OF RELEVANCY

- 1) References AF and AP - AT have been cited in the International Search Report. A copy of these references is being submitted herewith.
- 2) References have been cited in the corresponding Search Report. A copy of these references is being submitted herewith.
- 3) References AA, AG and AU-AX are discussed in the specification. A copy of these references is being submitted herewith.
- 4) References are additional prior art known to Applicant. A copy of these references is being submitted herewith.